-

Shareholder Alert: Robbins LLP Announces PlayAGS, Inc. (AGS) Sued for Misleading Shareholders

SAN DIEGO & LAS VEGAS--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of PlayAGS, Inc. (NASDAQ: AGS) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2018 and August 7, 2019. PlayAGS designs and supplies gaming products and services for the gaming industry in the United States and internationally.

If you suffered a loss as a result of PlayAGS' misconduct, click here.

PlayAGS, Inc. (AGS) Accused of Misleading Shareholders

According to the complaint, on March 5, 2019, PlayAGS announced in its 2019 outlook an expected adjusted EBITDA of $160-$164 million, representing growth of approximately 17%-20% compared to 2018. On May 8, 2019, PlayAGS continued to tout its positive financials, announcing an increase of 13% in total revenue for first quarter 2019 due to "continued growth in [its] [electronic gaming machine] segment, primarily [selling] units in… Michigan, Saskatchewan, Pennsylvania, and Massachusetts." However, PlayAGS failed to disclose that the Company had been experiencing challenges in Oklahoma that would negatively impact its revenue. This impact was revealed on August 7, 2019, when PlayAGS reported a net loss of $7.6 million for second quarter 2019, including a $3.5 million impairment to goodwill and another $1.3 million impairment in iGaming reporting unit due to extended regulatory timelines that delayed revenues. PlayAGS also cut its 2019 expected adjusted EBITDA to $145-$150 million, now representing growth of only 6%-10% from 2018. On this news, PlayAGS' stock declined $8.99 per share, or 52%, closing at $8.31 per share on August 8, 2019.

If you purchased PlayAGS, Inc. (AGS) securities between August 2, 2018 and August 7, 2019, you have until August 4, 2020, to ask the court to be appointed lead plaintiff for the class.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against PlayAGS settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:AGS

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom